



## NOW FROM GLAUKOS

Using Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5'-phosphate ophthalmic solution), and the KXL® system, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.\*1



# GET THERE IN TIME

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve your patients' vision.

See back cover for Important Safety Information and visit [livingwithkeratoconus.com](http://livingwithkeratoconus.com) for full prescribing information.


\*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

GLAUKOS®

# Transforming the standard of care for progressive keratoconus

In clinical studies, cross-linking-treated eyes showed increasing improvement in  $K_{max}$  from month 3 through month 12, while in untreated, sham eyes,  $K_{max}$  demonstrated steepening.<sup>1</sup>


## Change From Baseline ( $K_{max}$ )—Progressive Keratoconus Patients\*<sup>1</sup>




\*Post-baseline missing data were imputed using last available  $K_{max}$  value. For the sham study eyes that received CXL treatment after baseline, the last  $K_{max}$  measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. In Study 3, 4 patients in the CXL group had missing baseline  $K_{max}$  value and were excluded from the analysis.  
CXL=corneal cross-linking.

## Cross-linking using UVA and riboflavin<sup>2</sup>

- Creates new corneal collagen cross-links
- Results in a shortening and thickening of collagen fibrils
- Leads to stiffening of the cornea



LESS CROSS-LINKING (WEAKER)



MORE CROSS-LINKING (STRONGER)

# Offers a proven safety profile<sup>1</sup>

## iLink™ keeps keratoconus from calling the shots

Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. More than half of these patients could need multiple transplants within 20 years.<sup>3,4</sup>

**OVER 400,000**

CROSS-LINKING PROCEDURES HAVE BEEN PERFORMED WORLDWIDE WITH OUR EQUIPMENT<sup>5</sup>


**APPROVED IN 2016**

IN THE UNITED STATES FOLLOWING 2 SUCCESSFUL PHASE III TRIALS<sup>1</sup>

## Understanding the science

### iLink™ proprietary procedure<sup>6</sup>

- iLink™ combines ultraviolet light with ambient oxygen and Photrexa® bioactivated ophthalmic solution
- Absorption of UVA by Photrexa® generates radical riboflavin to form cross-links
- Precise, metered UV light delivery with the KXL system
- Backed by 20 years of science to achieve the right formulation




Both the American Academy of Ophthalmology and the Cornea Society recommend cross-linking for the treatment of progressive keratoconus.<sup>7,8</sup>

# Diagnose and treat progressive keratoconus

Keratoconus may be vastly underdiagnosed, underestimated, and underserved<sup>9</sup>



Left unchecked, progression can lead to a higher risk of vision loss, significantly reduced vision quality of life, and the potential need for a corneal transplant.<sup>10,11</sup>



Prevalence was as high as **1 in 375** in a recent Netherlands study, which is **5 to 10** times higher than previously reported.<sup>12</sup>



Onset occurs from 12 years of age through 20 years of age for a vast majority of patients.<sup>13</sup>



Vision loss is associated with anxiety, depression, potential loss of independence, and a heavier burden on family members and/or social services.<sup>10</sup>

## Offer your patients the benefits of iLink™

- Peace of mind
- The only therapeutic treatment option for progressive keratoconus
- May reduce or delay the need for more invasive procedures<sup>14</sup>
- One-time procedure widely covered by commercial medical insurance<sup>15</sup>

# Take control with the iLink™ procedure

As a minimally invasive procedure, the iLink™ cross-linking procedure is the new standard of care for progressive keratoconus. With extensive clinical validations, iLink™ is proven safe and efficacious in numerous trials and peer-reviewed publications.<sup>1,7</sup>



## The proprietary iLink™ procedure incorporates:

### The KXL System

- UVA irradiation: 30 minutes at 3 mW/cm<sup>2</sup>
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity



### Photrexa® and Photrexa® Viscous

- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards



PHOTREXA™  
(RIBOFLAVIN 5'-PHOSPHATE OPHTHALMIC SOLUTION) 0.146%



PHOTREXA™ VISCOUS  
(RIBOFLAVIN 5'-PHOSPHATE IN 20% DEXTRAN OPHTHALMIC SOLUTION) 0.146%

# Reimbursement support and tools give patients access to iLink™

**OVER 95%** COMMERCIAL INSURANCE COVERAGE



Financial feasibility tools available



National team of dedicated reimbursement experts



Billing, coding, preauthorization, claims, and appeals resources available



Flexible options for equipment acquisition



Uninsured and Medicaid available for qualified patients



Access to the Photrexa® cross-linking kit via Specialty Pharmacy

For the latest information on reimbursement, including insurers that cover iLink™, visit [Glaukos.com](http://Glaukos.com). Ask your Glaukos representative about seamlessly integrating iLink™ into your practice.

## Cost efficiencies may be possible when iLink™ is performed early in the disease stage

Slowing or halting disease progression with a single outpatient procedure may be a more cost-effective option for patients than ongoing management approaches.<sup>15</sup>

# GLAUKOS<sup>®</sup>

**Glaukos is a global pioneer in the ophthalmic market with novel therapies that provide sustainable solutions for important clinical needs.**

**Our focus** is to develop and lead the global ophthalmic market with therapies for glaucoma and corneal and retinal diseases through continual innovation and investment.

**Our mission** is to transform treatment and provide therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.



## CREATING FIRSTS WITH MANY MORE ON THE HORIZON

- First minimally invasive glaucoma surgery (MIGS) device commercially available in the United States
- Smallest medical device ever implanted in humans
- First and only FDA-approved procedure proven to slow or halt progression of keratoconus

# iLink™ slows or halts progression to help you preserve vision

- Only FDA-approved cross-linking procedure
- Wide reimbursement coverage
- Backed by Glaukos comprehensive support

FOR MORE INFORMATION ON iLink™, VISIT [GLAUKOS.COM](http://GLAUKOS.COM) OR CONTACT YOUR GLAUKOS REPRESENTATIVE

## REFERENCES:

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.
2. Beshawi IM, O'Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. *J Cataract Refract Surg.* 2013;39(3):451-462.
3. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. *Ophthalmology.* 2006;113(9):1633-1638.
4. Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. *Eye Contact Lens.* 2014;40(6):382-389.
5. Data on File, Glaukos, Inc.
6. Kamaev P, Friedman MD, Sherr E, Muller D. Photochemical kinetics of corneal cross-linking with riboflavin. *Invest Ophthalmol Vis Sci.* 2012;53:2360-2367.
7. Belin MW, Lim L, Rajpal RK, et al. Corneal cross-linking. *Cornea.* 2018;37(10):1218-1225.
8. Garcia-Ferrer FJ, Akpek EK, Amescua G, et al. 2018 American Academy of Ophthalmology: Corneal Ectasia Preferred Practice Patterns: Ophthalmol 2018;126(1)170-215.
9. Torres Netto EA, et al. Prevalence of keratoconus in paediatric patients in Riyadh, Saudi Arabia. *Br J Ophthalmol.* 2018;0:1-6.
10. Making Eye Health a Population Health Imperative: Vision for Tomorrow. Washington (DC): National Academies Press (US); 2016 Sep 15. 3. The Impact of Vision Loss.
11. Reeves S, Stinnett S, Adelman R, Afshari N. Risk Factors for Progression to Penetrating Keratoplasty in Patients With Keratoconus. *Am J Ophthalmol.* 2005.
12. Godefrooij D, De Wit G, Uiterwaal C, et al. Age-specific Incidence and Prevalence of Keratoconus: A Nationwide Registration Study. *Am J Ophthalmol.* 2017;175:169-172.
13. Valdez-García, J.E., Supúlveda R, Salazar-Martínez J.J., Lozano-Ramírez J. F., Prevalence of keratoconus in an adolescent population. *Revista Mexicana de Oftalmología.* 2014;88:95-98.
14. Godefrooij DA, Gans R, Imhof SM, Wisse RP. Nationwide reduction in the number of corneal transplantations for keratoconus following the implementation of cross-linking. *Acta Ophthalmol.* 2016;94(7):675-678.
15. Gray L. Understanding Keratoconus Treatment Costs. Avedro website. Accessed August 10, 2020. <https://www.livingwithkeratoconus.com/blog/understanding-keratoconus-treatment-costs/>

## INDICATIONS

Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking should not be performed on pregnant women.

## IMPORTANT SAFETY INFORMATION

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to [www.livingwithkeratoconus.com](http://www.livingwithkeratoconus.com) to obtain the FDA-approved product labeling. You are encouraged to report all side effects to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

**iLink™**  
CROSS-LINKING PROCEDURE

MA-01973A

© 2020 Glaukos Corporation. iLink™ is a trademark of Glaukos Corporation. Glaukos and Photrexa® are registered trademarks of Glaukos Corporation.

**GLAUKOS®**  
San Clemente, CA +1-949-367-9600



## NOW FROM GLAUKOS

Using Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5'-phosphate ophthalmic solution), and the KXL® system, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.\*1



# GET THERE IN TIME

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve your patients' vision.

See back cover for Important Safety Information and visit [livingwithkeratoconus.com](http://livingwithkeratoconus.com) for full prescribing information.


\*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

GLAUKOS®

# Transforming the standard of care for progressive keratoconus

In clinical studies, cross-linking-treated eyes showed increasing improvement in  $K_{max}$  from month 3 through month 12, while in untreated, sham eyes,  $K_{max}$  demonstrated steepening.<sup>1</sup>


## Change From Baseline ( $K_{max}$ )—Progressive Keratoconus Patients\*<sup>1</sup>




\*Post-baseline missing data were imputed using last available  $K_{max}$  value. For the sham study eyes that received CXL treatment after baseline, the last  $K_{max}$  measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. In Study 3, 4 patients in the CXL group had missing baseline  $K_{max}$  value and were excluded from the analysis. CXL=corneal cross-linking.

## Cross-linking using UVA and riboflavin<sup>2</sup>

- Creates new corneal collagen cross-links
- Results in a shortening and thickening of collagen fibrils
- Leads to stiffening of the cornea



LESS CROSS-LINKING (WEAKER)



MORE CROSS-LINKING (STRONGER)

# Offers a proven safety profile<sup>1</sup>

## iLink™ keeps keratoconus from calling the shots

Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. More than half of these patients could need multiple transplants within 20 years.<sup>3,4</sup>

**OVER 400,000**

CROSS-LINKING PROCEDURES HAVE BEEN PERFORMED WORLDWIDE WITH OUR EQUIPMENT<sup>5</sup>


**APPROVED IN 2016**

IN THE UNITED STATES FOLLOWING 2 SUCCESSFUL PHASE III TRIALS<sup>1</sup>

## Understanding the science

### iLink™ proprietary procedure<sup>6</sup>

- iLink™ combines ultraviolet light with ambient oxygen and Photrexa® bioactivated ophthalmic solution
- Absorption of UVA by Photrexa® generates radical riboflavin to form cross-links
- Precise, metered UV light delivery with the KXL system
- Backed by 20 years of science to achieve the right formulation




Both the American Academy of Ophthalmology and the Cornea Society recommend cross-linking for the treatment of progressive keratoconus.<sup>7,8</sup>

# Diagnose and treat progressive keratoconus

Keratoconus may be vastly underdiagnosed, underestimated, and underserved<sup>9</sup>



Left unchecked, progression can lead to a higher risk of vision loss, significantly reduced vision quality of life, and the potential need for a corneal transplant.<sup>10,11</sup>



Prevalence was as high as **1 in 375** in a recent Netherlands study, which is **5 to 10** times higher than previously reported.<sup>12</sup>



Onset occurs from 12 years of age through 20 years of age for a vast majority of patients.<sup>13</sup>



Vision loss is associated with anxiety, depression, potential loss of independence, and a heavier burden on family members and/or social services.<sup>10</sup>

## Offer your patients the benefits of iLink™

- Peace of mind
- The only therapeutic treatment option for progressive keratoconus
- May reduce or delay the need for more invasive procedures<sup>14</sup>
- One-time procedure widely covered by commercial medical insurance<sup>15</sup>

# Take control with the iLink™ procedure

As a minimally invasive procedure, the iLink™ cross-linking procedure is the new standard of care for progressive keratoconus. With extensive clinical validations, iLink™ is proven safe and efficacious in numerous trials and peer-reviewed publications.<sup>1,7</sup>



## The proprietary iLink™ procedure incorporates:

### The KXL System

- UVA irradiation: 30 minutes at 3 mW/cm<sup>2</sup>
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity



### Photrexa® and Photrexa® Viscous

- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards



PHOTREXA™  
(RIBOFLAVIN 5'-PHOSPHATE OPHTHALMIC SOLUTION) 0.146%



PHOTREXA™ VISCOUS  
(RIBOFLAVIN 5'-PHOSPHATE IN 20% DEXTRAN OPHTHALMIC SOLUTION) 0.146%

# Reimbursement support and tools give patients access to iLink™

**OVER 95%** COMMERCIAL INSURANCE COVERAGE



Financial feasibility tools available



National team of dedicated reimbursement experts



Billing, coding, preauthorization, claims, and appeals resources available



Flexible options for equipment acquisition



Uninsured and Medicaid available for qualified patients



Access to the Photrexa® cross-linking kit via Specialty Pharmacy

For the latest information on reimbursement, including insurers that cover iLink™, visit [Glaukos.com](http://Glaukos.com). Ask your Glaukos representative about seamlessly integrating iLink™ into your practice.

## Cost efficiencies may be possible when iLink™ is performed early in the disease stage

Slowing or halting disease progression with a single outpatient procedure may be a more cost-effective option for patients than ongoing management approaches.<sup>15</sup>

# GLAUKOS®

**Glaukos is a global pioneer in the ophthalmic market with novel therapies that provide sustainable solutions for important clinical needs.**

**Our focus** is to develop and lead the global ophthalmic market with therapies for glaucoma and corneal and retinal diseases through continual innovation and investment.

**Our mission** is to transform treatment and provide therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.



## CREATING FIRSTS WITH MANY MORE ON THE HORIZON

- First minimally invasive glaucoma surgery (MIGS) device commercially available in the United States
- Smallest medical device ever implanted in humans
- First and only FDA-approved procedure proven to slow or halt progression of keratoconus

# iLink™ slows or halts progression to help you preserve vision

- Only FDA-approved cross-linking procedure
- Wide reimbursement coverage
- Backed by Glaukos comprehensive support

FOR MORE INFORMATION ON iLink™, VISIT [GLAUKOS.COM](http://GLAUKOS.COM) OR CONTACT YOUR GLAUKOS REPRESENTATIVE

## REFERENCES:

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.
2. Beshawi IM, O'Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. *J Cataract Refract Surg.* 2013;39(3):451-462.
3. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. *Ophthalmology.* 2006;113(9):1633-1638.
4. Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. *Eye Contact Lens.* 2014;40(6):382-389.
5. Data on File, Glaukos, Inc.
6. Kamaev P, Friedman MD, Sherr E, Muller D. Photochemical kinetics of corneal cross-linking with riboflavin. *Invest Ophthalmol Vis Sci.* 2012;53:2360-2367.
7. Belin MW, Lim L, Rajpal RK, et al. Corneal cross-linking. *Cornea.* 2018;37(10):1218-1225.
8. Garcia-Ferrer FJ, Akpek EK, Amescua G, et al. 2018 American Academy of Ophthalmology: Corneal Ectasia Preferred Practice Patterns: Ophthalmol 2018;126(1)170-215.
9. Torres Netto EA, et al. Prevalence of keratoconus in paediatric patients in Riyadh, Saudi Arabia. *Br J Ophthalmol.* 2018;0:1-6.
10. Making Eye Health a Population Health Imperative: Vision for Tomorrow. Washington (DC): National Academies Press (US); 2016 Sep 15. 3. The Impact of Vision Loss.
11. Reeves S, Stinnett S, Adelman R, Afshari N. Risk Factors for Progression to Penetrating Keratoplasty in Patients With Keratoconus. *Am J Ophthalmol.* 2005.
12. Godefrooij D, De Wit G, Uiterwaal C, et al. Age-specific Incidence and Prevalence of Keratoconus: A Nationwide Registration Study. *Am J Ophthalmol.* 2017;175:169-172.
13. Valdez-García, J.E., Supúlveda R, Salazar-Martínez J.J., Lozano-Ramírez J. F., Prevalence of keratoconus in an adolescent population. *Revista Mexicana de Oftalmología.* 2014;88:95-98.
14. Godefrooij DA, Gans R, Imhof SM, Wisse RP. Nationwide reduction in the number of corneal transplantations for keratoconus following the implementation of cross-linking. *Acta Ophthalmol.* 2016;94(7):675-678.
15. Gray L. Understanding Keratoconus Treatment Costs. Avedro website. Accessed August 10, 2020. <https://www.livingwithkeratoconus.com/blog/understanding-keratoconus-treatment-costs/>

## INDICATIONS

Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa™ (riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking should not be performed on pregnant women.

## IMPORTANT SAFETY INFORMATION

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to [www.livingwithkeratoconus.com](http://www.livingwithkeratoconus.com) to obtain the FDA-approved product labeling. You are encouraged to report all side effects to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

**iLink™**  
CROSS-LINKING PROCEDURE

MA-01973A

© 2020 Glaukos Corporation. iLink™ is a trademark of Glaukos Corporation. Glaukos and Photrexa® are registered trademarks of Glaukos Corporation.

**GLAUKOS®**  
San Clemente, CA +1-949-367-9600